Merck Spinoff Organon to Buy Alydia Health for $240 Million
Merck has entered into an agreement that will see its planned spinoff company Organon acquire Alydia Health, a developer of postpartum hemorrhage (PPH) devices, for $240 million.
The deal will include Alydia Health’s Jada System, an FDA-cleared device that is intended to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is necessary. Organon CEO Kevin Ali said that the company will seek authorizations for the system in Europe and elsewhere.
The acquisition, expected to close in the late second quarter of the year, “aligns with Organon’s strategy to become a global leader in woman’s health by focusing our product development on her unmet medical needs,” Ali said.